. Ishikawa cells were cytokeratin+/vimentin2 and expressed ERa, ERb, PR and GnRH-R proteins. At 6 and 24 h, neither LA nor GA alone had an effect on gene expression. GnRH analogues alone or following E 2 and/or P4 co-incubation for 24 h also had no effect on gene expression, but P4 significantly increased expression of CHMP1A. E 2 + P4 treatment for 4 days, alone or followed by GA, had no effect, but E 2 + P4 treatment followed by LA significantly decreased IGFBP-5 expression. The addition of 8-Br cAMP did not modify gene expression, with the exception of IGFBP-5 that was significantly increased. The GnRH analogues did not modify intracellular cAMP levels. We identified conserved EREs for OPN, CHMP1A, SNX7 and PSAP and PREs for SNX7. We conclude that GnRH analogues appear not to have major direct effects on gene expression of human endometrial epithelial cells in vitro.
Introduction
Gonadotrophin-releasing hormone (GnRH) is a decapeptide with a critical role in reproduction. A second GnRH type (GnRH-II) is expressed in the midbrain, hippocampus and other areas of the hypothalamus (Cui et al., 2000; Millar, 2003; Cheng and Leung, 2005; Wu et al., 2009a and b) . Numerous studies have demonstrated that GnRH receptors (GnRH-R) exist in different reproductive tissues such as the ovary, placenta, endometrium, and also in endometrial cancer cells (Millar et al., 2001 (Millar et al., , 2003 Ramakrishnappa et al., 2005; Cheung and Wong, 2008) . GnRH and GnRH-II receptors are present in the endometrium, with highest levels reported in the secretory phase followed by a decline in the decidua (Dong et al., 1998; Raga et al., 1998; Takeuchi et al., 1998; Borroni et al., 2000; Gründker et al., 2001; Shemesh, 2001) . It has been reported that GnRH can act in an autocrine and paracrine manner to suppress cell proliferation and activate apoptosis in the endometrium as well as in endometrial cancer cells (Hsueh and Jones, 1981; Cheung and Wong, 2008) . Both GnRH and GnRH-II exhibit regulatory roles in tissue remodeling during decidualization, embryo invasion and placentation (Cheon et al., 2001; Paria et al., 2002; Chou et al., 2003) .
The GnRH analogues are commonly used as adjuvants to gonadotrophins in controlled ovarian hyperstimulation (COH) cycles in women undergoing assisted reproductive technologies (ARTs) to prevent a premature LH surge. In addition to the established GnRH central action, the endometrial expression of GnRH and its receptor implies an additional site of action for GnRH analogues. It has been speculated that COH as performed during in vitro fertilization (IVF) therapy may negatively affect embryo implantation (Garcia et al., 1984; Gordon, 2001; Horcajadas et al., 2008) . Many questions remain about a controversial negative impact of GnRH antagonists on endometrial receptivity (Borthwick et al., 2003; Bourgain and Devroey, 2003; Al-Inany et al., 2007; Huang, 2008; Oehninger, 2008) .
We recently reported on a clinical study designed to investigate gene expression profiles of the human endometrium during the window of implantation of GnRH analogue-recombinant FSH-treated COH cycles in oocyte donors compared with temporally matched natural cycles (Mirkin et al., 2004) . Microarray results demonstrated significant variations in the expression of the following five genes: OPTI-NEURIN (OPTN) and PROCOLLAGEN TYPE III N-ENDOPEPTIDASE (or CHROMATIN MODIFYING PROTEIN 1A, CHMP1A), which were up-regulated in GnRH agonist-treated cycles versus natural cycle controls, PROSAPOSIN (PSAP) and IGF-BINDING PROTEIN-5 (IGFBP-5), which were up-regulated in GnRH antagonist-treated cycles versus natural cycle controls, and SORTING NEXIN 7 (SNX7), which was up-regulated in GnRH agonist cycles versus antagonist cycles (Mirkin et al., 2004) . The three genes that contributed the best discriminating expression profile (highest variations) by linear discriminant analysis (LDA) were OPTN, CHMP1A and SNX7, all of them significantly up-regulated in GnRH agonist-treated cycles.
On the other hand, estrogens and progesterone (P4) exert tissuespecific actions through interaction with their respective receptor subtypes, and following the interaction of these ligand -receptor complexes with effectors, which include different DNA-response elements and important co-regulator proteins (Jabbour et al., 2006) . The two isoforms of estrogen receptor, ERa and ERb, have been identified in mammals, exerting its action genomically through estrogenresponse elements (EREs) in a ligand-dependent fashion (Kato et al., 1995; Kuiper et al., 1997; Diel, 2002) . The identification of the palindromic sequence that defines EREs and P4-response elements (PREs) allows for the in silico discovery of putative hormone receptor targets in the genome.
Activation of the cyclic adenosine monophosphate (cAMP) pathway is an obligatory event that starts the critical process of endometrial decidualization (Gellersen et al., 2007) . Decidualization of endometrial stromal cells occurs in vivo in response to P4 and involves activation of the protein kinase A (PKA) pathway (Tierney et al., 2003) . After ovulation, the endometrium is increasingly exposed to a variety of local and endocrine factors that are capable of stimulating cAMP production in stromal cells, and adenylate cyclase activity in the human endometrium increases during the secretory phase (Gellersen et al., 2007) .
On the other hand, few reports have postulated regulation of endometrial epithelial cell functions by cAMP. Chan et al. (1999) were the first to provide direct evidence of a cAMP-activated Cl 2 conductance, presumably CFTR, in murine endometrial epithelial cells (Zheng et al., 2004) . On the other hand, Zhou et al. (1994) reported that hCG treatment increased expression of the COX-2 gene in human endometrial gland epithelial cells, using a cAMP/type I PKA signaling pathway. Within this context, the overall objective of this study was to examine the modulatory effects of GnRH analogues [leuprolide acetate (LA), a GnRH agonist, and ganirelix acetate (GA), a GnRH antagonist] on gene expression of human endometrial epithelial cells. To accomplish this goal, we used Ishikawa cells as a surrogate for human endometrial epithelium, a known and established in vitro cell culture model, originated from an endometrial adenocarcinoma and known to display ER and PR in culture (Nishida, 2002; Navarro et al., 2003; Bocca and Archer, 2005; Uchida et al., 2005) .
The specific aims were: (i) to characterize Ishikawa cells by immunofluorescence and immunocytochemistry [to confirm the epithelial cell origin and purity (cytokeratin+/vimentin2) and the protein expression of ERa, ERb, PR and GnRH-R] and by RT-PCR (for mRNA expression of ERa, ERb, PR, GnRH-R and GnRH-II-R); (ii) to study the in vitro modulatory effect of GnRH analogues (in the absence and presence of E 2 and P4 on mRNA expression of OPTN, CHMP1A, PSAP, IGFBP-5 and SNX7, endometrial genes previously shown to be modified in vivo by GnRH analogues in recombinant FSH-treated ART cycles (Mirkin et al., 2004 ) using quantitative, real-time RT -PCR and (iii) to analyze the 5 ′ -flanking regions of such genes for the presence of putative EREs and PREs (Mirkin et al., 2005) .
Materials and Methods

In vitro culture of Ishikawa cells
Ishikawa cells were kindly provided by Dr Paul Web (University of California, San Francisco, CA, USA). Ishikawa cells were cultured in DMEM/F-12 1:1 medium (Dulbecco's modified Eagle's medium/Ham's F-12; Gibco, Grand Island, NY, USA/Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS, Gibco) containing antibiotics (penicillin/streptomycin 1% vol./vol., Gibco), and 5 pg/ml insulin (Sigma) at 378C in a 95% air -5% CO 2 atmosphere. According to the individual experiment, once 50 -80% confluence was reached, Ishikawa cells were cultured for an additional 24-h-period in DMEM supplemented with charcoal-stripped and dextran-treated 2% FBS (Hyclone, Logan, UT, USA) and then subjected to different treatments as shown in Experiments 1 -4. Cell structural integrity was assessed by inverted microscopy (Navarro et al., 2003) . The GnRH analogues studied were LA (Abott Laboratories, North Chicago, IL, USA) and GA (Organon, Roseland, NJ, USA).
Immunofluorescence and immunocytochemistry
The epithelial origin and purity of Ishikawa cells were assessed by immunofluorescent analysis of cytokeratin and vimentin, specific markers for epithelial and stromal cells, respectively (specific antibodies obtained from Abcam, Cambridge, MA, USA); anti-cytokeratin antibody was used in 1:100 dilution anti-vimentin antibody in 1:50 dilution. Immunofluorescence was also used for the detection of GnRH-R with a mouse monoclonal anti-GnRH-R antibody (1:25 dilution, Abcam). Mouse non-immune IgG (isotype control, eBioscience, San Diego, CA, USA) was used as the negative control, and goat anti-mouse bound to FITC in a 1:150 dilution was used as the secondary antibody. DAPI was used to counterstain the nuclei. Slides were mounted with anti-fading medium (Vector Laboratories, Burlingame, CA, USA) and analyzed under fluorescence microscopy (Nikon Eclipse E600) equipped with a SPOT-RT Slider digital camera (Diagnostic Instruments Inc., Sterling, MI, USA). Immunohistochemistry was performed for ERa, ERb and PR on cultured Ishikawa cells. Briefly, endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 10 min, and non-specific binding sites were blocked with 2% normal goat serum (NGS) for 60 min at room temperature. The primary antibodies for ERa, ERb and PR (mouse monoclonal, Abcam) were serially diluted in a solution of PBS-2% NGS to optimize sensitivity and specificity and used at a dilution of 1:25. After primary antibody incubation, sections were washed three times with PBS and incubated with biotinylated goat anti-mouse secondary antibody (Abcam) at a dilution of 1:120 for 30 min at room temperature. After rinsing with PBS, the immunoreactive antigen was visualized by incubating with avidinbiotinylated horseradish peroxidase (1:100) complex for 30 min and 3,3 ′ -diaminobenzidine (0.5 mg/ml) as chromagen for 3 min to complete the reaction. Negative controls included sections that were treated with the omission of the primary antibody. Slides were counterstained with Mayer's hematoxylin (Sigma) followed by dehydration in a graded series of ethanol, cleared in xylene, and mounted with mounting media. Representative fields were photographed at ×200 and ×400 magnification with an Olympus microscope (Olympus Corp., Tokyo, Japan) using an Olympus Q-color 3 camera.
Quantitative real-time RT-PCR
We investigated mRNA expression of ERa, ERb, PR, GnRH-R and GnRH-II-R (to further characterize Ishikawa cells) and OPTN, CHMP1A, PSAP, IGFBP-5 and SNX7 (to study the possible modulatory effects of GnRH analogues). After incubations, cells were washed, scraped and total RNA was extracted using an RNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The quality of total RNA extracted was analyzed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and quantification of total RNA was performed on a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA).
cDNA was generated from 300 ng of total RNA in a total volume of 20 ml containing: 2.5 mM random hexamers, 2.5 U/ml murine leukemia virus reverse transcriptase, 1U/ml RNase inhibitor, 1x PCR buffer, 1 mM each deoxy-NTP, 5 mM MgCl 2 (Applied Biosystems, Foster City, CA, USA). RT parameters were as follows: 238C for 10 min, 428C for 15 min (RT reaction), 998C for 5 min (transcriptase deactivation) and 58C for 5 min in an iCycler thermal cycler (BioRad, Hercules, CA, USA). cDNA solutions were then stored at 2208C. Preparations without reverse transcriptase were used as negative controls, in which the absence of PCR products indicated a complete lack of contaminating genomic DNA.
Quantitative real-time PCR was performed using a Lightcycler Fastart DNA Master Plus SYBR green I and a Lightcycler 2.0 instrument (Roche Applied Science, Indianapolis, IN, USA) in a 20-ml total reaction volume, containing 2-ml cDNA and 0.5 mM of each sense and antisense primers (except GADPH which was used at 0.3 mM).
Before amplification, samples were denatured at 958C for 10 min. The template was amplified by 45 cycles of denaturation at 958C for 10 s, annealing of primers at the specific temperature as given in Table I for 5 s and extension at 728C for 10 s, followed by a final extension at 728C for 10 min. The melting protocol consisted of heating the samples to 958C followed by cooling to 658C for 15 s and slowly heating at 0.18C per second to 958C while monitoring fluorescence. Melting curve analysis was performed after each run to verify specific amplification. Negative control consisted of PCR water replacing the cDNA solution (no template control). All PCR products exhibited a single peak in melting curves and were identified as single bands of the appropriate size on ethidium bromide-stained 3% agarose gel electrophoresis. In addition, amplification specificity was confirmed by sequencing all PCR products, after purification using QIAquick kit (Qiagen), performed by UC Davis, CA, USA (http://dnaseq.ucdavis.edu/SoftwareDownloads.html). All PCR products demonstrated 97-99% homology with the respective human sequences. cDNA levels were determined using a standard curve and the values obtained were normalized to those found for GADPH (housekeeping gene) to account for differing amounts of starting material (Franchi et al., 2008) . Table I presents oligonucleotides (primer sequences) used for real-time PCR, annealing temperatures and expected amplicon/PCR product sizes.
In silico promoter analysis for EREs and PREs
For in silico identification of EREs and PREs, we used two tools, DEREF (Dragon ERE Finder) (Bajic et al., 2003) 
GnRH analogues and their effects on human endometrial epithelial cells http://apps.sanbi.ac.za/PRE/index.php). DEREF has been designed to achieve high sensitivity and high specificity on promiscuous ERE sequences. DEREF has been designed to achieve high sensitivity and high specificity. It makes, on an average, 1 prediction in 13 300 nucleotides in two stranded search at a sensitivity of 83%, which makes it very useful for selective predictions of EREs. For the present analysis, search for EREs is performed using a sensitivity of 87%. DPREL model uses dinucleotide position-weight matrices and is designed on the same principles, but achieves much better performance of 96% sensitivity while making one prediction in 67 780 nucleotides in the randomly selected human DNA (204 358 000 nucleotides). It is used with its default setting. It should be noted that DEREF and DPREL differ in the way how they report position of the motif on the complementary strand. DEREF reports the actual position where the motif starts (counted from the 5 ′ end of the forward strand), and the motif spreads towards the 5 ′ end of the forward strand. DPREL, however, reports the position that corresponds to the 3 ′ end of the motif on the complementary strand. The reason for this difference is that it is easier to observe when the palindromic patterns are predicted on both strands.
Promoters
For the genes of interest, we extracted promoter regions that correspond to 3000 bp upstream and 200 bp downstream (23000, +200) relative to the 5 ′ end of Exon1. The ortholog promoter sequences of 11 mammalian species (including human) were extracted using TOUCAN 2 (Aerts et al., 2005) . The ortholog species included were human, cow, dog, hedgehog, elephant, opossum, monkey, mouse, rabbit, chimp and rat.
Experiments Experiment 1
Objective: to determine whether the GnRH agonist LA modulates expression of OPTN, CHMP1A and SNX7. Following initial culture as depicted earlier, and after 80% confluence, Ishikawa cells were treated for 6 h with three GnRH agonist concentrations (0.01, 0.1 and 1 mM) versus untreated controls.
Rationale: the selection of these three genes was based upon the application of LDA to the clinical data mentioned earlier (Mirkin et al., 2004) . The examined concentrations of LA were based on the therapeutic plasma serum levels after subcutaneous administration in the clinical setting (Klemmt et al., 2009) . Studies have previously shown modulation of gene expression in endometrial cells as early as 1 -6 h of stimulation (Tierney et al., 2003) .
Experiment 2
Objective: to examine the impact of short-time E 2 and/or P4 co-incubation (24 h) on the effect of GnRH analogues on gene expression (examined genes: OPTN, CHMP1A and SNX7 for GnRH agonist, and IGFBP-5 and PSAP for GnRH antagonist). The examined conditions were: untreated controls, E 2 (10 nM for 24 h) (Sigma), P4 (10 nM for 24 h) (Sigma), LA (1 mM for 24 h), GA (1 mM for 24 h), E 2 (10 nM for 12 h) followed by P4 (10 nM for 12 h) and E 2 (10 nM) plus LA or GA (1 mM for 12 h) followed by P4 (10 nM for 12 h).
Rationale: E 2 and P4 modulate the effect of GnRH analogues on gene expression.
Experiment 3
Objective: to examine the impact of higher dose and longer time E 2 -and P4-priming conditions on the effect of GnRH analogues on gene expression (OPTN, CHMP1A, SNX7, IGFBP-5 and PSAP). The examined conditions were: untreated controls, E 2 (30 nM) plus P4 (1 mM) for 4 days, E 2 (30 nM) plus P4 (1 mM) for 4 days followed by the GnRH agonist LA (1 mM for 6 h) and E 2 (30 nM) plus P4 (1 mM) for 4 days followed by the GnRH antagonist GA (1 mM for 6 h).
Rationale: the longer treatment mimics the time needed for in vitro decidualization of stromal cells, which has been shown to peak at Day 3 of culture (Klemmt et al., 2009 ); as such, we speculated that longer sex steroid priming of epithelial cells might result in a more robust gene regulation.
Experiment 4
Objective: to examine the impact of a cAMP analogue (8-bromo-cAMP, Sigma) on the effect of GnRH analogues on gene expression. The examined conditions were: untreated controls, cAMP (1 mM for 24 h), cAMP (1 mM for 24 h) followed by the GnRH agonist LA (1 mM for 6 h) and cAMP (1 mM for 24 h), followed by the GnRH antagonist GA (1 mM for 6 h).
Rationale: the effect of GnRH analogues on endometrial epithelial cells gene expression may be modulated by cAMP. It has been reported that cAMP analogues modulate endometrial (stromal) cell gene expression during decidualization. These effects were observed at short treatment times (0-6 h, cell cycle regulation), intermediate times (12-24 h, cellular differentiation including genes regulating cell morphology and secretory patterns) and later periods (24-48 h, immunomodulatory genes) (Tierney et al., 2008) .
Additionally, GnRH has been shown to induce production of cAMP in the pituitary gonadotrophs, resulting in increased gene expression and release of newly synthesized LH (reviewed in Counis et al., 2005) . As such, we also tested whether GnRH analogues resulted in the modification of intracellular cAMP levels in Ishikawa cells, using a cAMP enzyme immunoassay kit, following manufacturer's recommendations (R&D Systems, Minneapolis, MN, USA). Intracellular cAMP concentrations were measured after GnRH analogues treatments (0.1, 1 and 10 mM) in a 30-min incubation period. The known activator of adenylate cyclase Forskolin (30 mM, Sigma) was used as a positive control.
Statistical analysis
Three different (independent) experiments were performed for each GnRH analogue, dose, time and E 2 , P4 and cAMP treatment condition. Gene expression levels (relative gene expression to GADPH) were compared using one-way analysis of variance. The Holm -Sidak and Dunnet post hoc tests for pair-wise multiple comparisons were used as appropriate. P , 0.05 values were considered statistically significant. Data are presented as mean + standard error of the mean. 
Results
Characterization of Ishikawa cells
Treatments results
Experiment 1
There was no significant effect of the GnRH agonist LA on the expression of the examined genes (OPTN, CHMP1A and SNX7) at any concentration tested (0.01, 0.1 and 1 mM) after 6 h of incubation (n ¼ 3 different experiments for each gene, P . 0.1, Fig. 3 ).
Experiment 2
This experiment examined whether short co-incubation time (24 h) with E2 and P4 had an impact on the effect of the GnRH analogues to modify gene expression (n ¼ 3 different experiments for each GnRH analogue and each gene studied). Neither E 2 (10 nM), LA (1 mM), GA (1 mM) alone, nor the E 2 + P4 co-treatment (with or without each analogue) had a significant effect on gene expression versus control levels (P . 0.1, data not shown). The only exception was the finding that P4 alone resulted in significantly higher gene expression of CHMP1A (P ¼ 0.03) than control levels (Fig. 4A) .
Experiment 3
This experiment investigated the impact of higher dose and longer time (4 days) of E 2 (30 nM) and P4 (1 mM)-priming on the effect of GnRH GnRH analogues and their effects on human endometrial epithelial cells analogues (after 6 h of incubation) on gene expression (n ¼ 3 different experiments for each GnRH analogue and each gene studied).
For OPTN, CHMP1A, SNX7 and PSAP genes: E 2 + P4 alone for 4 days, or followed by the GnRH agonist LA or the GnRH antagonist GA, had no effect on the relative expression levels of any of these genes (P . 0.1, data not shown). On the other hand, for IGFBP-5 gene: E 2 + P4 treatment for 4 days followed by LA (but not GA) after 6 h significantly decreased mRNA expression levels versus control (P ¼ 0.03) (Fig. 4B ).
Experiment 4
This study examined the impact of pretreatment with the cAMP analogue (8-bromo-cAMP) for 24 h on the effect of GnRH analogues on Ishikawa cell gene expression (n ¼ 3 different experiments for each GnRH analogue and each gene studied). For OPTN, CHMP1A, SNX7 and PSAP genes, none of the treatments (cAMP alone, and with a GnRH agonist or GnRH antagonist) affected gene expression levels (P . 0.1, data not shown). For IGFBP-5 gene, expression levels were significantly increased by cAMP alone (P ¼ 0.002), as well as by cAMP with the GnRH agonist LA (P ¼ 0.0007) and the GnRH antagonist GA (P ¼ 0.0003). Neither LA nor GA significantly augmented the effect observed with cAMP alone (Fig. 4C) .
In addition, neither GnRH analogue (at 0.1, 1 and 10 mM for 30 min incubation) resulted in significant changes of cAMP levels as measured by an enzyme immunoassay (P . 0.1 versus controls), whereas forskolin resulted in a significantly increased production, P , 0.05, Fig. 4D ).
Identification of EREs and PREs in the genes studied
Prediction of EREs
EREs of length 17 bases were searched for on ortholog promoters of each gene (OPTN, CHMP1A, SNX7, PSAP and IGFBP-5). Results are presented in Table II .
OPTN: at a sensitivity of 87%, we were able to predict 12 EREs on promoters of 6 species including human, monkey, mouse, rabbit, chimp and rat. We found the element TT-GGCCA-GGC-TGGTC-TC (shown in red) fully conserved in human, monkey and chimp promoters.
CHMP1A: at a sensitivity of 87%, we were able to predict two EREs on promoters of two species. The identified EREs were conserved between human and chimp, with one mismatch in the spacing nucleotide and another in the most 3 ′ -flanking nucleotide.
SNX7:
we identified seven different EREs on the promoters of six orthologous species. Two EREs TT-GGCCA-GAT-TGGCC-AA and TT-GGCCA-ATC-TGGCC-AA were fully conserved in the promoters of human and chimp (shown in red and pink, respectively) and a conservation of 16 nucleotides was observed in monkey for both EREs, with the only 1 nucleotide mismatch in each case, either as the most 5 ′ -flanking position or the most 3 ′ -flanking position.
Elephant and rabbit promoters contain fully conserved element AA-GGACT-AGC-TAACC-AC. PSAP: DEREF predicted EREs on promoters of eight orthologous species. Human and chimp promoters have completely conserved 
Prediction of PREs
PREs of length 15 bases were searched for on 10 ortholog promoters of each of OPTN, CHMP1A, SNX7, PSAP and IGFBP-5 genes. We were not able to predict PREs on the promoters of four of these genes, OPTN, CHMP1A, PSAP and IGFBP-5 for any of the species we tested. SNX7: two different PREs were identified on the promoters of SNX7 genes in three species (Table II) . The element AGGA-CATGGTGTTCT was identified in the promoters of human and chimp species (shown in red). The results suggest that only SNX7 is likely controlled by P4, whereas the other three genes are not.
Discussion
Ovarian stimulation for IVF is known to affect luteal phase function. Questions about the impact of the use of GnRH analogues, particularly antagonists, have been raised. A recent Cochrane review (Al-Inany et al., 2007) described lower pregnancy rates in women treated with a GnRH antagonist, compared with those using an agonist, despite the fact that GnRH antagonist is a more effective repressor of LH. The endometrium in IVF cycles is subjected to an altered endocrinological environment (particularly hyperestrogenism secondary to gonadotrophin stimulation, but also to high levels of P4 secondary to the presence of multiple functioning corpora lutea and/or exogenous supplementation). In addition, there is also a plausible direct effect of the GnRH analogues on the endometrium. The question still remains whether the previously reported differences in endometrial gene expression in COH cycles performed with GnRH analogues and gonadotrophins result in endometrial changes having a major functional impact on embryo implantation (Bourgain and Devroey, 2003; Martínez-Conejero et al., 2007; Huang, 2008; Oehninger, 2008) .
Here, we used Ishikawa cells as surrogate of human endometrial epithelial/glandular cells. The functional nature of Ishikawa cells was validated through the characterization of epithelial cell origin and purity (cytokeratin+/vimentin2), confirmation of protein expression of ERa, ERb, PR and GnRH-R and presence of mRNA transcripts of ERa, ERb, PR, GnRH-R and GnRH-II-R. We elected to study five endometrial genes that were significantly altered (up-regulated) in the luteal phase of IVF cycles (using gonadotrophins and GnRH analogues) as evidenced by our previous microarray analysis (Mirkin et al., 2004) . Other authors have reported similar and other altered gene expression profiles using parallel approaches (Carson et al., 2002; Kao et al., 2002; Riesewijk et al., 2003; Horcajadas et al., 2008; Macklon et al., 2008) .
Two of these five genes (PSAP and IGFBP-5) have functions previously linked to endometrial physiology. The previously recorded presence of PSAP in the endometrium (epithelial cells) suggests roles for this protein in glycosphingolipid metabolism or transport in the uterine environment, and these functions appear to be steroid dependent (Spencer et al., 1995) . On the other hand, the IGF system plays a fundamental role in endometrial biology, acting via autocrine and/or paracrine mechanisms (Zhou et al., 1994) . IGFBPs regulate the mitogenic and metabolic actions of IGFs by inhibiting or, in some cases, enhancing the receptor binding of IGF. IGFBPs have an important role in the regulation of endometrial cellular mitosis, stroma-glandular relation and embryo-endometrial communication (Zhou et al., 1994; Mohan and Baylink, 2002; White et al., 2005) .
OPTN is a 74-kDa protein implicated in the signal transduction of the tumor necrosis factor pathway and has been implicated in membrane traffic regulation, cellular morphogenesis and apoptosis (Hattula and Peränen, 2000) . SNX7 contains a phox domain, which is a phosphoinositide-binding domain, with a fundamental role in orchestrating the formation of protein complexes that are involved in endosomal sorting and signaling (Cullen, 2008) . Similarly, the CHMP1A gene encodes a member of the CHMP/Chmp family of proteins which are involved in multivesicular body sorting of proteins to the interiors of lysosomes. The initial prediction of the protein sequence encoded by this gene suggested that the encoded protein was a metallopeptidase. The nomenclature has been updated recently to reflect the correct biological function of this encoded protein (Li et al., 2008) .
Our results demonstrated that the GnRH agonist LA, in the absence of sex steroids, did not have a direct effect on the expression levels of OPTN, CHMP1A and SNX7 (the three main target genes identified by LDA analysis in our previous analysis of COH cycles) (Mirkin et al., 2004) in Ishikawa cells. We examined different doses of the agonist (range of 0.1 -1 mM) at both short (6 h) and longer (24 h) incubation times (Experiments 1 and 2). In addition, the GnRH antagonist GA did not modify expression of PSAP or IGFBP-5 at 24 h, in the absence or presence of 24-h sex steroids treatment (Experiment 2). The GnRH analogues LA and GA also resulted in unmodified levels of intracellular cAMP, a known second messenger resulting from receptor activation by its specific ligand in the pituitary gonadotrophs (Experiment 4). 
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On the other hand, sex steroid treatment affected expression of some of the genes studied. P4 alone (24-h incubation) resulted in significantly higher gene expression of CHMP1A than control conditions. Furthermore, for IGFBP-5, E 2 + P4 pretreatment for 4 days followed by LA (but not GA) after 6 h significantly decreased mRNA expression levels versus control (Experiment 3). Because sex steroid hormones, whether under physiological or supraphysiological conditions as seen in COH cycles, may act through specific response elements, we investigated the presence of putative EREs and PREs. On its own, the presence of hormone-response elements (HREs) in the promoter region 
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GnRH analogues and their effects on human endometrial epithelial cells of a gene is not evidence of the hormonal control of expression of that gene. However, the presence of HREs in a promoter suggests that such HRE sites could be used by activated hormone receptors and consequently could affect gene expression. The supporting evidence for this could be strengthened if similar HREs could be identified in the promoters of orthologous genes. This would suggest evolutionary conservation of HRE sites across various species, implying potential importance of the presence of such sites. Our analysis covered these aspects. The analysis of the predicted EREs on the promoters of the target genes showed that there is a consistent conservation of patterns of EREs in the promoters of the closely related orthologous species. This conservation might be an indicator of the control of these genes through the EREs. In cases where there is conservation of the ERE across human, chimp and monkey, such as for OPTN and SNX7, we can hypothesize that the EREs conserved between them are the active ERE sites in primates. These conclusions are derived on the basis of considering individual target genes and their respective orthologs.
Further evidence indicative of the importance of the predicted EREs would be the conservation of EREs across different human target genes. Table III represents the conservation of EREs predicted at a sensitivity of 87% in the promoters of all the genes under analysis. EREs (shown in red) are present in the promoters of four of the human genes under study. For OPTN, CHMP1A and PSAP, the ERE pattern is preserved in 16 out of 17 nucleotides, with mismatch only on the most 3 ′ -flanking nucleotide. The pattern is 100% preserved in CHMP1A and PSAP genes. Moreover, in four target genes, both half-sites are fully conserved. This strongly suggests that these EREs could be active sites. On the basis of these results, we conclude that all four target genes have a potential to be controlled by estrogen. In summary, the in silico prediction of EREs and PREs in the promoters of the five target genes and their orthologs from other mammalian species suggest that most of these genes (OPTN, CHMP1A SNX7 and PSAP) have support for their potential control by E 2 and one gene (SNX7) by P4. Conversely, we did not identify EREs or PREs for IGFBP-5 (Table IV) .
Notwithstanding the presence of putative EREs and PREs and their likely significance for steroid hormone in vivo regulation, the in vitro treatment of Ishikawa cells with E 2 + P4 (for 24 h or 4 days) did not affect per se the expression of most studied genes. In fact, although EREs were identified for OPTN, CHMP1A, SNX7 and PSAP, and PREs were identified for SNX7, gene expression was not modulated by sex steroid treatment under the Ishikawa cell culture conditions studied herein, with the exceptions of CHMP1A and IGFBP-5. It remains to be determined whether higher doses and/or longer preincubation times (as possibly seen in COH cycles) might affect gene expression patterns as we described previously in the in vivo studies (Mirkin et al., 2004) , either directly or through effects of stromal products acting on a paracrine fashion.
Progesterone alone enhanced expression of CHMP1A at 24 h, in spite of the fact that we could not identity PREs for this gene, , 2006) . Moreover, the GnRH agonist LA, but only after E 2 + P4 pretreatment for 4 days, significantly decreased mRNA expression levels of IGFBP-5. The lack of identification of EREs and PREs for this gene also suggests sex steroid priming through other non-classical pathways. This is supported by the fact that there are several pathways for the activation of estrogencontrolled genes that are not based on the binding of estrogen receptor to EREs (Nilsson and Gustafsson, 2000; Harrington et al., 2006) . At least two microarray studies have shown that IGFBP-5 was up-regulated in COH cycles where GnRH antagonists were used in combination with gonadotrophins, with (Mirkin et al., 2004) or without P4 supplementation of the luteal phase (Macklon et al., 2008) . It has been reported that IGFBP-5 gene expression is inhibited by P4 during the natural cycle (Giudice et al., 1991; Zhou et al., 1994) and is down-regulated in vitro in decidualized endometrial stromal cells by cAMP acting through PKA activation (Tierney et al., 2003) . In the study of Mirkin et al. (2004) , there were no differences in the serum steroid levels on the day the endometrial biopsies were performed (matched cycle Day 21) between COH cycles accomplished with GnRH antagonist with P4 supplementation, GnRH antagonist without P4 supplementation or GnRH agonist with P4 supplementation. According to Macklon et al. (2008) , up-regulation of IGFBP-5 in the P4 non-supplemented cycles was unanticipated, as this IGFBP is the only one whose expression is suppressed in the secretory phase, compared with the proliferative phase. As such, Macklon et al. (2008) also concluded that dysregulation of the endometrial transcriptome in the stimulated cycle is not fully attributable to supraphysiological sex steroid levels at the folliculo-luteal transition.
Our results using Ishikawa cells, however, did not demonstrate an effect of GnRH antagonist on IGFBP5; rather, the GnRH agonist modulated expression of IGFBP-5, and this effect resulted in a significant down-regulation. The fact that modulation of gene expression by the GnRH agonist was observed after a 4-day E 2 + P4 priming period suggests interaction between sex steroid modulation and the agonist. Since we were not able to identify EREs or PREs for this gene, it can be speculated that the sex steroids might regulate the epithelial cell through non-classic mechanisms. O'Brien et al. (2006) demonstrated that estrogen-induced responses in the uterus can be divided into classical and non-classical pathways by using genetic models that selectively discriminate between these mechanisms. The non-classical pathway, which is ERE independent and functions probably via protein -protein interactions with transcription factors and/or signals via rapid, nongenomic pathways originating at the cell membrane, mediates the estrogen-dependent epithelial cell proliferation and growth responses, whereas the classical pathway, where the ER binds directly to an ERE to activate or repress gene expression, is required for other responses, such as hyperemia and water imbibition.
We also found that IGFBP-5 was the only gene modulated by cAMP analogue treatment. IGFBP-5 gene expression levels were significantly increased by cAMP alone as well as by cAMP with the GnRH agonist LA and the GnRH antagonist GA, but neither LA nor GA significantly augmented the effect observed with cAMP alone (Experiment 4). The cAMP analogue significantly up-regulated IGFBP-5 expression upon 24 h of incubation, an effect that was not subjected to further modulation by either of the GnRH analogues. It appears, therefore, as though IGFBP-5 is a potential target gene of several regulatory mechanisms (steroids, GnRH and cAMP) in endometrial epithelial cells. The observed effect of cAMP on epithelial cells differs from the stromal compartment where IGFBP-5 was down-regulated in vitro by decidualized stromal cells by cAMP acting through PKA activation (Tierney et al., 2003) .
Reports from several other laboratories have established that GnRH analogues can modulate the expression of other genes, particularly in endometrial stromal cells in vitro. In fact, TIMP-1 and -3 (tissue inhibitors of matrix metalloproteinases) mRNA expression and protein secretion into the medium were significantly decreased by a GnRH agonist compared with control groups (Raga et al., 1999) , whereas IL-1B mRNA expression and protein expression were significantly enhanced by a GnRH agonist (Raga et al., 2008) . Other studies have demonstrated that GnRH analogues can induce apoptotic cell death in endometrial epithelial cells and endometriotic cells in vitro (Meresman et al., 2003 , Bilotas et al., 2007 . Moreover, GnRH agonists have been shown to act directly on isolated stromal cells (primary cultures) and in epithelial cell lines altering the expression and activation of SMADS, intracellular signals activated by transforming growth factor-b (Luo et al., 2003) . Nevertheless, the results of our study do not demonstrate a direct effect of GnRH analogues on the genes studied in the Ishikawa epithelial cell model. Klemmt et al. (2009) recently analyzed the in vitro effects of GnRH analogues on the decidualizing endometrium and blastocyst invasion. The concentrations of the GnRH analogues they used were also based on the physiological plasma serum levels after systemic administration, while the time of incubation of 72 h was selected to allow for in vitro decidualization. The authors demonstrated that GnRH analogues did not significantly influence the extent of decidualization of endometrial stromal cells in vitro. In addition, no adverse effects of GnRH analogues were seen on human blastocyst invasion. They concluded that GnRH analogues affect neither the capacity of the endometrium to support invasion nor the invasive potential of the blastocyst in the early stages of implantation. Our results are similar as related to endometrial epithelial cells, since at the concentrations and time periods used in our studies we did not detect any direct actions of the GnRH antagonists on the tested genes, except for the E 2 + P4-primed down-regulation of IGFB-5 by the GnRH agonist. The results of these two studies appear to be consistent with the outcome of a clinical report showing no impact on pregnancy, following the use of a GnRH antagonist administered throughout the estrogenic phase in recipients of donor eggs (Prapas et al., 2009 gene expression; (ii) GnRH agonist down-regulated IGFBP-5 following long-term sex steroid priming, but IGFBP-5 lacked ERE and PRE; we speculate that this effect is mediated through the identified GnRH-R and via a cAMP-independent mechanism; (iii) cAMP up-regulated IGFBP-5 expression, and more studies are needed to examine the pathways and significance of cAMP-derived actions and (iv) most target genes demonstrated the presence of conserved EREs, posing the question as to estrogen regulation under other experimental conditions or in the in vivo scenario. The observed down-regulation of IGFBP-5 gene expression in vitro by the GnRH agonist coincides with patterns seen in the natural cycle, and as such it may not have a significant functional effect at the endometrial level. We conclude, based on the experimental conditions described in Ishikawa cells, that GnRH analogues appear not to have major direct effects on gene expression of human endometrial epithelial cells in vitro.
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